Studies two heart stents in routine care for coronary artery disease
Observes how the Ultimaster stents perform in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice
Key facts
- Where
- Chuncheon, Daegu, Daejeon, Gangneung, Kwangju, Pusan, Seoul, and Suncheon, South KoreaSee the 11 sites
Where in South Korea
- Gangwon National Univ. HospitalChuncheon, South KoreaNo longer taking part
- Daegu Catholic University Medical CenterDaegu, South KoreaTaking people
- Keimyung University - Dongsan Medical CenterDaegu, South KoreaTaking people
- The Catholic University of Korea, Daejeon ST.Mary's HospitalDaejeon, South KoreaTaking people
- Gangneung Asan HospitalGangneung, South KoreaTaking people
- Kwangju Christian HospitalKwangju, South KoreaTaking people
- Pusan National University HospitalPusan, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Kangdong Sacred Heart HospitalSeoul, South KoreaTaking people
- The Catholic Univ. of Korea Eunpyeong St. Mary's hospitalSeoul, South KoreaNo longer taking part
- St.Carollo HospitalSuncheon, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Duk-Woo Park, MD
- Trial code
- NCT04443530
- Record updated
- 26 June 2026
- Original description
This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.Read full original descriptionShow less
Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.
Inclusion: Patients ≥ 19 years old; Patients receiving Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stents; The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion: Patients with a mixture of other drug-eluting stents (DESs); Terminal illness with life-expectancy ≤1 year; Patients with cardiogenic shock.